Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apricoxib
- Development stage
- Phase 2
- Lead developer
- Cothera Bioscience
- Modality
- Small Molecules
01
Overview
Apricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor. It was developed for its anti-inflammatory and antineoplastic properties, particularly in treating cancers such as non-small cell lung cancer and pancreatic cancer. Apricoxib has shown potential in reversing epithelial-to-mesenchymal transition (EMT), a process involved in cancer progression and metastasis.
- Brand names
- Capoxigem
- Other names
- apricoxib
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on apricoxib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apricoxib.